Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505309 | 0.79 | TDP1 (0.40) | TDP1TSHRFFAR3ALDH1A1 | |
| SCHEMBL8380273 | 0.79 | TDP1 (0.40) | TDP1TSHRFFAR3ALDH1A1 | |
| SCHEMBL14661666 | 0.77 | CPT2 (0.38) | TDP1TSHRPTGS1FFAR3ALDH1A1 | |
| SCHEMBL8277447 | 0.77 | CPT2 (0.38) | TDP1TSHRPTGS1FFAR3ALDH1A1 | |
| SCHEMBL18611857 | 0.77 | ALDH1A1 (0.32) | TDP1TSHRPTGS1KCNH2ALDH1A1 | |
| SCHEMBL14661898 | 0.77 | CPT2 (0.38) | TDP1TSHRPTGS1FFAR3ALDH1A1 | |
| SCHEMBL1781697 | 0.77 | ALDH1A1 (0.32) | TDP1TSHRPTGS1KCNH2ALDH1A1 | |
| SCHEMBL18697963 | 0.75 | CA1 (0.37) | TSHRPTGS1KCNH2 | |
| SCHEMBL13201631 | 0.73 | — | — | |
| SCHEMBL19387492 | 0.73 | TP53 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TDP1 768/4885TSHR 3626/4885PTGS1 1254/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TDP1 768/4885TSHR 3626/4885PTGS1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.